Shaun McNulty

AWAKN Life Sciences, Inc. provides evidence-based psychedelic assisted psychotherapy solutions. The company is headquartered in Toronto, Canada.

Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The private company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry.

Inflection Biosciences Ltd. is an Irish drug development company that focuses on discovering and developing small molecule therapeutics to address major unmet needs in cancer, autoimmune, and inflammatory diseases. Inflection Biosciences is based in Blackrock, IE. The private company's pipeline includes IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML, and multiple myeloma, and the IBL-100 series, which comprises selective pan-PIM kinase inhibitors. The partnered pipeline includes AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences.